Cystic Kidney Diseases From the Adult Nephrologist’s Point of View

Roman-Ulrich Müller* and Thomas Benzing

Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany

Cystic kidney diseases affect patients of all age groups with the onset spanning from prenatal disease to late adulthood. Autosomal-dominant polycystic kidney disease (ADPKD) is by far the most common renal cystic disease. However, there are various cystic kidney diseases, the onset of which occurs at different times in life and depends on the type of the disease and the causative genes involved. When genetic kidney diseases are discussed in the adult setting this view is usually limited on autosomal-dominant kidney disease, the most frequent genetic disorder causing adult onset ESRD. Other diseases—such as autosomal-recessive polycystic kidney disease—are often being viewed as a disorder only important in pediatric nephrology. However, more recent data has revealed that, despite clear age peaks of onset for each disorder, all of them can also show highly variable phenotypes with classical adult onset genetic diseases being of importance in pediatrics and vice versa. Furthermore, the affected children need to be seen by adult nephrologists in the long term after transition, requiring knowledge on the underlying pediatric disease, potential extrarenal manifestations, and genetic counseling. Consequently, the view on these diseases should be widened on both ends. Close interaction between pediatric and adult nephrology is key to appropriate care of patients suffering from genetic kidney disease to profit from each other’s experience.

Keywords: polycystic kidney diseases, autosomal dominant polycystic kidney disease, autosomal-recessive polycystic kidney disease, tuberous sclerosis complex, von Hippel-Lindau disease, nephronophthisis, genetic kidney disease, Birt–Hogg–Dubé syndrome

INTRODUCTION

While pediatric nephrologists are rather experienced in managing patients with genetic kidney diseases, most adult nephrologists are faced with congenital disease less frequently (1, 2). This is mainly due to the reason that genetic disorders are the minority of causes of end-stage renal disease in the adult population whereas in children they are common. Autosomal-dominant polycystic kidney disease (ADPKD) reveals most of its burden in adulthood and has long been considered to be the only cystic kidney disease in adults. Other cystic kidney diseases—primarily nephronophthisis (NPH) and autosomal-recessive polycystic kidney disease (ARPKD)—start much earlier and are entities that have primarily been studied and treated by pediatric nephrologists. However, with the advent of the first targeted treatment strategies—such as tolvaptan in ADPKD patients—the question arises whether early detection of disease and an early commencement of a potential therapy may be beneficial.

Genetic causes of kidney disease are on the brink to become much more of a visible problem in adult nephrology. This is not limited to cystic kidney diseases, but also true for other disorders, such as the MCD-FSGS spectrum. On the one hand, an increasing number of children suffering from kidney disease reach adulthood raising the question of transition and continued care in the adult nephrology setting. On the other hand, the advent of novel sequencing technologies has paved the way for elucidating more complex genetic factors in kidney disease and will allow for novel associations...
between the genetic background and pathogenic aspects. Clearly, chronic kidney disease in general in adulthood has an important genetic component. However, many of the genetic alterations are not simply monogenetic causes, but must rather be considered as complex genetic diseases. Consequently, knowledge on genetic diseases of the kidney will play an increasingly important role in adult nephrology and profit from a close interaction with colleagues from pediatric nephrology. Here, we will use the example of cystic kidney diseases—and ADPKD specifically—to point out the most important aspects and advances in the care of adult patients.

**CYSTIC KIDNEY DISEASE—A CILIOPATHY**

The introduction of next-generation sequencing techniques in the last decade—starting in basic research and being currently introduced in clinical diagnostics—made the large-scale analysis of potential disease-causing mutations in patients with cystic kidney diseases feasible (3–6). This has led to the identification of numerous novel disease-causing genes enabling the discovery of more than 100 genes to be involved in cystic kidney diseases (7). Nonetheless, a significant proportion of cases remains unsolved which will require further research in well-characterized families and cohorts (3, 5). Despite this enormous genetic complexity of cystic kidney diseases, they are unified by a single pathophysiological concept. Nearly all protein products of disease-causing genes identified so far have been linked to the generation or function of the primary cilium—a membraneous protrusion of the apical cell membrane of close to all cell types that is supported by a microtubular skeleton (7). Primary cilia may function as chemo- and mechanoreceptors and ciliary dysfunction which initiates numerous signaling aberrations in epithelial kidney cells—like increased cAMP generation or mTOR-signaling—that are crucial to cyst formation (8). This has led to the definition of the cystic disease complex as a ciliopathy. The fact that pretty much all tissues in the human body contain ciliated cells explains why ciliary defects can be the basis to complex syndromes affecting different organs—e.g., the combination of cystic kidneys with *situs inversus* and retinitis pigmentosa observed in several NPH-associated syndromes (9).

**ADPKD—EPIDEMIOLOGY**

Autosomal-dominant polycystic kidney disease is the most common entity among cystic kidney diseases (10). Its lifetime morbid risk is estimated to be around 1:1,000 while point prevalence—which rather reflects clinically relevant disease—has recently been shown to be approximately 1:2,500 (11–14). The frequency of ADPKD is thus comparable to much more commonly known disorders, including autosomal-dominant tubulointerstitial disease (ADTKD), NPH, and ARPKD and a clear separation from different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts. (1) Autosomal-dominant polycystic kidney disease generally goes along with enlarged kidneys. Since the disease is gradually progressing during lifetime, size has to be considered in an age-dependent fashion. The correlation of age-adjusted kidney size with disease progression allows for using the information obtained by imaging to—beyond making a diagnosis—help guiding treatment decisions using, e.g., MRI volumetry (19) (Figure 1). Large polycystic kidneys are also found in ARPKD as well as in the much less common tumor-associated syndromes (tuberous sclerosis, Von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome) and *HNF1b*-associated kidney disease (20–22). In contrast to this, diseases of the NPH complex are characterized by small (to normal) sized kidneys. (2) Ravine et al. were the first to come up with a classification based on cyst numbers that allowed for diagnosing ADPKD in individuals at risk, imaging modalities are highly important screening tools. As to this point, several different key factors have to be taken into consideration: (1) kidney size, (2) number of cysts, (3) unilateral/bilateral disease, and (4) distribution of the cysts.
Renal Manifestations Beyond Cysts

As to the kidneys themselves, ADPKD is not only characterized by renal cysts but also includes kidney stones, flank pain, cyst infections, and macrohematuria. While these manifestations are common in adult patients and may lead to the diagnosis—especially in cases with a negative family history—they are rare in childhood. Importantly, early onset of these symptoms may indicate rapid progression of disease as pointed out by the data from the French GENKYST cohort (PROPKD score, see section on “Targeted therapies”) (28).

Extrarenal Manifestations

As explained above cystic kidney diseases are one of the best characterized ciliopathies. Knowing that cilia are present on nearly all cells of the human body and are expected to play important roles in cellular polarity signaling and cell proliferation it is not surprising that the clinical manifestation of a ciliopathy is normally not limited to one organ, but causes a multitude of syndromic clinical pictures. Knowledge of the extrarenal manifestations is crucial to patient care, since they do not only explain symptoms but may also require specific interventions/diagnostic strategies—e.g., in the case of intracranial aneurysms in ADPKD. As to diagnosing a specific cystic kidney disease these manifestations are very helpful, especially in cases where the decision is not clear based on kidney morphology. Hence, a complete workup of these aspects by patient history and clinical examination is essential when seeing PKD patients.

Extrarenal Manifestations in ADPKD

The most common extrarenal finding in ADPKD patients is extrarenal cysts with the majority of patients also showing liver cysts (and less frequently in other organs, such as the seminal vesicles, pancreas, or spleen). Furthermore, diverticulosis is a common manifestation. As to cardiac manifestations cardiac valve abnormalities—primarily mitral valve prolapses and insufficiency—are the most common findings, a fact that makes echocardiography a useful tool in the workup of these patients. Abdominal and inguinal hernias are also associated with ADPKD and are probably a consequence of both an altered strength of the abdominal wall and the increased intra-abdominal pressure due to enlarged kidneys and liver. An aspect that may be especially worrisome for ADPKD patients is the increased occurrence of intracranial aneurysms. Here, a tailored screening strategy in high-risk patients (e.g., those with a positive family history) as well as an interdisciplinary workup (neurosurgeons, neuroradiologists, nephrologists) are crucial—especially when taking into account that interventions to close these aneurysms can also lead to significant morbidity and mortality (29, 30). A more complete workup of potential extrarenal associations with ADPKD and their management can be found in the recent literature (10, 31, 32).

Extrarenal Manifestations of Tumor Syndromes Associated With Polycystic Kidneys

In contrast to ADPKD, the tumor syndromes—associated with polycystic kidneys that often resemble ADPKD—tuberous sclerosis, BHD syndrome, and VHL syndrome—all go along with a significantly increased risk of kidney cancer (clear-cell renal cell carcinoma in VHL and TSC; chromophobe renal cell carcinoma...
in BHD). Furthermore, all of these syndromes have characteristic extrarenal manifestations—TSC: e.g., giant-cell astrocytomas and other CNS tumors, renal angiomylipomas, pulmonary lymphangioleiomyomatosis, cardiac rhabdomyomas, and multiple dermatological signs (facial angiofibromas, periungual fibromas, ash leaf spots, Shagreen patches, etc.); BHD: recurrent pneumothoraces and fibrofolliculomas; VHL: e.g., CNS/retinal hemangioblastomas, pancreatic neuroendocrine tumors, and pheochromocytoma (33). All of these can and should be used for differential diagnosis. While VHL and BHD patients often do not show any symptoms before late adolescence or adulthood, TSC—especially due to the CNS and cardiac manifestations—is frequently already highly symptomatic in early childhood. Nonetheless, there are a considerable proportion of TSC patients that are not diagnosed before adulthood and present with an oligosymptomatic course that, e.g., is mainly characterized by multiple renal angiomylipomas.

**Extrarenal Manifestations in ARPKD and HNF1B-Associated Kidney Disease**

Another disease that can phenocopy the renal phenotype of ADPKD patients is ARPKD. However, the spectrum of extrarenal manifestations differs between these two entities. While in childhood pulmonary hypoplasia is one of the most dramatic findings, patients reaching adulthood without having been diagnosed do generally not show pulmonary symptoms. However, ARPKD has an obligatory association with liver fibrosis (in combination with dilated bile ducts—Caroli syndrome). Consequently, these patients need a workup, including liver imaging (sonography, fibroscan) and gastroscopy (screening for varices). Combined kidney-liver transplantation always needs to be considered when reaching end-stage renal disease (34).

HNF1b is a key transcription factor influencing numerous renal and extrarenal disease genes. Consequently, its mutation can lead to a range of symptoms. As to extrarenal manifestation-associated disorders, which include elevated liver enzymes, MODY diabetes mellitus, pancreatic insufficiency, hypomagnesemia, hyperparathyroidism, gout, and mental retardation (22).

**Extrarenal Manifestations in Diseases of the NPH Complex**

Even though diseases of the NPH complex are much less common in the adult population knowledge about their characteristics is important for identifying individuals affected by non-ADPKD cystic kidney diseases. Due to the nature of these disorders as a ciliopathy a wide range of affected tissues and symptoms are possible. In the following, we will summarize the most common examples that may sometimes not be diagnosed before reaching adulthood (9). Importantly, the attribution of a disorder to the NPH complex is—due to genetic complexity—not primarily guided by genetic diagnostics, but by the clinical characterization of the syndromic pattern of manifestations. The most frequent extrarenal finding in NPH patients is retinitis pigmentosa, which is characterized by night blindness followed by tunnel vision and eventually blindness. The combination of NPH and retinitis pigmentosa is classified as Senior–Løken syndrome. Furthermore—based on the role of cilia at the primary node during embryonal determination of laterality—many patients with NPH-associated syndromes show *situs inversus* as a characteristic finding. Another entity to be specifically named here is Bardet–Biedl syndrome which is characterized by polydactyly, juvenile obesity (often accompanied by diabetes mellitus), mental retardation of different degrees, retinitis pigmentosa, anosmia, and hypogonadism. Interestingly, Bardet–Biedl patients often show large kidneys at birth. While kidney size in the majority returns to normal by the age of 1–2 years, renal phenotypes that resemble ADPKD have been described in adult patients. Most other diseases of the NPH complex are nearly exclusively diagnosed in early childhood, such as Joubert syndrome (characterized by cerebellar vermis hypoplasia) or result in perinatal lethality as for Meckel–Gruber syndrome (20).

**The Role of Genetic Diagnostics**

Using the clinical criteria mentioned above, the diagnosis can be made correctly in the vast majority of patients without requiring a molecular genetics workup (20, 25, 35). In NPH, there is only very limited phenotype–genotype correlation which makes targeted genetics difficult. However, since *NPHP1* is the most commonly affected gene, testing for alterations in *NPHP1* may be of diagnostic utility (36, 37). This may change in the future with always cheaper and easier access to next-generation sequencing panels. ADPKD is—in patients with a positive family history—diagnosed almost exclusively on clinical grounds. However, molecular genetics may play a major important role in these patients for predicting disease progression (which may be a piece of the puzzle for making therapeutic decisions) in the future (28). The tumor syndromes on the other hand require different considerations when discussing molecular genetics. Here, a clear diagnosis based on the mutation is essential to distinguish these entities from ADPKD which then allows for the design of screening strategies for individual patients and prognostic testing in family members. An overview of a diagnostic strategy in cystic kidney diseases including clinical and genetic considerations is illustrated in (Figure 2). Importantly, current clinical diagnostic algorithms may require adaptation in the future due to novel culprit genes and associated disease entities identified—e.g., *GANAB* recently described as a new gene in ADPKD (5). Obviously, diseases not expected in adulthood—e.g., ARPKD and rare disorders that go along with variable clinical manifestations like HNF1b-associated kidney disease—may also require a molecular genetic diagnosis.

**CLINICAL TRIALS TO PREVENT DISEASE PROGRESSION OF CYSTIC KIDNEY DISEASE**

**Supportive Measures**

Knowledge of the various manifestations is key to the therapy of cystic kidney diseases in general. ESRD can obviously be addressed by renal transplantation in all entities (with a combined liver transplantation to be considered in ARPKD patients). Yet, data from randomized trials as well as a targeted therapy are only available for ADPKD. Until the year 2015 merely
supportive measures were available. The most important recommendations to all of the affected individuals are summarized in Table 1, however, the degree of evidence is limited for some of these recommendations. As an example, sufficient fluid intake is mainly based on pathophysiological considerations regarding ADH-suppression (38–40). Here, a recently initiated randomized trial will hopefully clarify the impact of fluid intake (41). On the contrary, there is solid data regarding blood pressure control which was recently emphasized again by the randomized HALT-PKD trials (42). Study arm A showed that lowering blood pressure to 95/60–110/70 mmHg compared to 120/70–130/80 mmHg using an ACE-inhibitor or an AT1-blocker leads to a significant decrease in the kidney growth rate (42) in young patients with preserved kidney function (15–49 years of age, CKD stages G1 and 2). Dual RAAS-blockade once again did not show any additional benefit (43). Interestingly, a post hoc analysis of the same trial confirmed that salt restriction should be part of the general management of ADPKD patients (44).

**Targeted Therapies—Tolvaptan**

The TEMPO 3:4 trial which was published in 2012 entirely changed the approach to ADPKD, since it led to the approval of
TABLE 1 | Supportive measures in autosomal-dominant polycystic kidney disease (ADPKD).

Supportive measures in ADPKD

| Blood pressure control (42) |
| Limiting NaCl intake to <5–7 g/day (44) |
| Sufficient fluid intake (>3 L/day) (39–41) |
| Avoid estrogen intake (which stimulates liver growth) (45–47) |
| Healthy diet (e.g., Mediterranean diet) (48, 49) |

While strict blood pressure control is based upon the results from an RCT (HALT-PKD study arm A), the strongest data regarding limiting salt intake specifically in ADPKD relies on a post hoc analysis of HALT-PKD. The effect of estrogens was observed both in pregnant women and more specifically in a small cohort regarding postmenopausal substitution. As to healthy diets, trial results regarding cardiovascular endpoints—the risk of which is increased in ADPKD—can be extrapolated to this cohort. Sufficient fluid intake inhibits ADH secretion, however, its impact on disease progression still needs to be confirmed.

The very first targeted therapy in Europe. TEMPO 3:4 showed—in a double-blind randomized design—that vasopressin receptor (V2R) inhibition could significantly slow down the rate of kidney growth by close to 50% (50). Even more importantly, eGFR loss was decreased by about 26%, an effect size that is comparable to the large trials on RAAS-blockade in diabetic nephropathy. This effect has recently been confirmed by the REPRISE trial that showed tolvaptan to be effective not only in early-stage ADPKD but also in patients having reached early CKD stage G4 (51). As expected V2R-blockade goes along with significant polyuria. Nonetheless, close to 80% of patients enrolled did continue through 3 years of the trial; a finding that is confirmed by recent real-world experiences (52). Furthermore, even though rare and reversible, liver toxicity is possible and requires regular screening of liver enzymes. In order for ADPKD patients to benefit from this therapy, careful selection of patients in whom the treatment is started is of utmost importance. Individuals that will not reach ESRD during lifetime are not suitable candidates for such an approach making only rapid progressors candidates for this therapy. Consequently, several publications have been published in the past 2 years trying to give guidance to nephrologists as to patient selection (27, 53). Past data on eGFR loss is the best indicator of rapid disease progression, yet, these data are not always available and do not help in CKD stage G1. Consequently, a row of predictors of disease progression in ADPKD—including models using total kidney volume ("Mayo classification") (19), mutation status, and clinical symptoms ("PROPKD Score") (28)—have been validated that can help in treatment decisions and patient counseling. While ultrasonography is usually sufficient to make a diagnosis of ADPKD, MRI volumetry has proven very helpful to obtain more precise kidney volumes as the basis to treatment decisions (Figure 1). A more detailed summary of these criteria can be found in the recent literature (27, 53).

Targeted Therapies Beyond Tolvaptan

Even though tolvaptan is a major step forward in the care of ADPKD patients it only slows down disease progression and will not prevent reaching ESRD in the vast majority of patients. Consequently, additional strategies targeting others of the multiple dysregulated cellular signal transduction pathways are necessary (54). One promising target was the mTOR-signaling pathway based on data from mouse models (55, 56). However, two clinical trials did unfortunately not show any benefit in the patient setting (57, 58). The use of somatostatin-analogs targets the same intracellular secondary messenger—cAMP—as tolvaptan. A small trial has shown a potential benefit in ADPKD patients (59). Currently, two phase 3 trials—the LIPS trial in France and the DIPAK1 trial in the Netherlands—are examining this approach in larger cohorts. Somatostatin-analogs would have the advantage to also influence liver disease in ADPKD, while an impact on the hepatic involvement has by now not been shown in the case of tolvaptan. Interestingly, with the use of pravastatin in ADPKD, a double-blind randomized trial in children and young adults has added another potential target (60). Even though a recent post hoc analysis of the HALT-PKD trials could not confirm a disease-modifying effect of statin therapy in ADPKD, final clarification of the potential of these drugs will need a larger prospective clinical trial (61). With the overactivation of several kinases in ADPKD, re-purposing of kinase inhibitors has gained interest in the past years. In this line, a phase 2 trial examining the potential of bosutinib—a src/bcr-abl tyrosine kinase inhibitor—has recently been published. In this 2-year trial, bosutinib was able to slow down kidney growth. However, there was no effect on eGFR loss and close to 50% of the patients discontinued the initial treatment period, primarily due to treatment-associated adverse events (62). Consequently, more efforts are necessary to continue translating basic research in ADPKD to clinically meaningful therapies. Apart from the identification of novel treatment targets and their translation into clinical trials—e.g., as for CDC25 inhibition using vitamin K3, treatment with niacinamide, re-purposing of metformin, dietary interventions, or reversal of the Warburg effect (63–67)—combination therapies could also help in improving the effects and reducing side effects of pharmacological therapies in ADPKD in the future (68, 69). Furthermore, as to tolvaptan, a trial that started recruitment in the past year is currently examining V2R-inhibition as a therapeutic principle in a pediatric cohort. Even though clinical disease onset in ADPKD does primarily occur in adulthood, patients with clear indicators of very rapid disease progression could profit from an early start of therapy making this trial an interesting endeavor.

CONCLUSION

There has been an enormous breakthrough in the understanding of polycystic kidney diseases both in the adult as well as in the pediatric population. A large number of underlying gene defects have been identified and pathogenic pathways characterized. In ADPKD this resulted in the development of the first available treatment strategies and the approval of tolvaptan to prevent progression of the disorder. Even though ADPKD is primarily a disease of adulthood and ADPKD patients are thus mainly seen by adult nephrologists, a close interaction between pediatric and adult nephrology will be of benefit to patients and their families. Not only do genetic diseases always involve more than one individual. Unusual courses can also...
lead to onset of classical diseases of adulthood (e.g., ADPKD) in children and of classical pediatric diseases (e.g., ARPKD and NPH complex) in adult patients. Adult nephrologists can benefit from the wide experience of pediatric disciplines regarding genetic diseases on the one hand. On the other hand, this interaction helps in combining the knowledge on childhood interventions with outcome in adulthood and allows to learn from each other’s experiences in the treatment of polycystic kidney diseases.

REFERENCES

1. Atkins RC. The epidemiology of chronic kidney disease. *Kidney Int Suppl* (2005) 67:S14–8. doi:10.1111/j.1523-1755.2005.09403.x
2. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. *Clin J Nephrol* (2016) 9:583–91. doi:10.1016/j.cjkn.2016.02.012
3. Schueler M, Munschauer M, Gregersen LH, Finzal A, Loewer A, Chen W, et al. Differential protein occupancy profiling of the mRNA transcriptome. *Genome Biol* (2014) 15:R15. doi:10.1186/gb-2014-15-1-r15
4. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. *Nat Engl J Med* (2011) 364:1533–43. doi:10.1056/NEJMr1010172
5. Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. *J Am Soc Nephrol* (2017) 29(1):13–23. doi:10.1681/ASN.2017050483
6. Lu H, Galeano MCR, Ott E, Kaeslin G, Kausalya PJ, Kramer C, et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. *Nat Genet* (2017) 49:1025–34. doi:10.1038/ng.3671
7. Braun DA, Hildebrandt F. Ciliopathies. *Cold Spring Harb Perspect Biol* (2017) 9(3):a028191. doi:10.1101/chsperspect.a028191
8. Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. *Nat Rev Nephrol* (2016) 12:133–46. doi:10.1038/nrneph.2015.205
9. Benzing T, Schermer B. Clinical spectrum and pathogenesis of nephropathies. *Curr Opin Nephrol Hypertens* (2012) 21:272–8. doi:10.1097/MNH.0b013e32835320f7
10. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. *Kidney Int* (2009) 76:149–68. doi:10.1038/ki.2009.128
11. Neumann HP, Ilg J, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. *Nephrol Dial Transplant* (2013) 28:1472–87. doi:10.1093/ndt/gfs551
12. McGovern AP, Jones S, van Vlymen J, Saggar AK, Sandford R, de Lusignan S. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. *BMC Nephrol* (2014) 15:182. doi:10.1186/1471-2369-15-182
13. Dalggaard OZ. Bilateral polycystic disease of the kidneys: a follow-up of 284 patients and their families. *Dan Med Bull* (1957) 4:128–33.
14. Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. *Nephrol Dial Transplant* (2017) 32:1356–63. doi:10.1093/ndt/gfw240
15. Hildebrandt F. Genetic kidney diseases. *Lancet* (2010) 375:1287–95. doi:10.1016/S0140-6736(10)60238-X
16. Marla N, Cuthell O, Langan D, Dudley J, Sinha MD, Winyard PJ. Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. *Arch Dis Child* (2016) 101:1142–7. doi:10.1136/archdischild-2015-310221
17. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival – an analysis of data from the ERA-EDTA registry. *Nephrol Dial Transplant* (2014) 29(Suppl 4):iv15–25. doi:10.1093/ndt/gfu017
18. Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents with ADPKD (Autosomal Dominant Polycystic Kidney Disease).

AUTHOR CONTRIBUTIONS

R-UM and TB wrote the manuscript. R-UM designed the figures.

FUNDING

Ministerium für Kultur und Wissenschaft des Landes NRW (Nachwuchsgruppen.NRW 2015-2021) Deutsche Nierenstiftung Marga und Walter Boll Stiftung.
36. Salomon R, Saunier S, Niaudet P. Nephronophthisis. *Pediatr Nephrol* (2009) 24:2333–44. doi:10.1007/s00467-008-0840-z
37. Schueller M, Halbritter J, Phillips IG, Braun DA, Otto EA, Porath JD, et al. Large-scale targeted sequencing comparison highlights extreme genetic heterogeneity in nephronophthisis-related ciliopathies. *J Med Genet* (2016) 53:208–14. doi:10.1136/jmedgenet-2015-103304
38. Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol* (2010) 5:693–7. doi:10.2215/CJN.01480609
39. van Gastel MDA, Torres VE. Polycystic kidney disease and the vasopressin pathway. *Ann Nutr Metab* (2017) 70:43–50. doi:10.1159/000463063
40. Wang CJ, Creed C, Winklhofer FT, Grantham JJ. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. *Clin J Am Soc Nephrol* (2011) 6:192–7. doi:10.2215/CJN.03950510
41. Wong AY, Manix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, et al. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). *BMJ Open* (2018) 8:e018794. doi:10.1136/bmjopen-2017-018794
42. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. *N Engl J Med* (2014) 371:2255–66. doi:10.1056/NEJMoa1402685
43. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. *N Engl J Med* (2014) 371:2267–76. doi:10.1056/NEJMoa1402686
44. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. *Kidney Int* (2017) 91:493–500. doi:10.1016/j.kint.2016.10.018
45. Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, et al. *Antihypertensive and Diuretic Agents – a KDIGO consensus report*. *Kidney Int* (2015) 88:676–83. doi:10.1038/ki.2015.28
46. Shersth R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. *Lancet* (2013) 382:1485–95. doi:10.1016/S0140-6736(13)64107-5
47. Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, et al. *Angiotensin II Receptor Blockers – a KDIGO consensus report*. *Kidney Int* (2014) 85:1856–71. doi:10.1038/ki.2014.202
48. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* (2013) 368:1279–90. doi:10.1056/NEJMoa1200303
49. Di Iorio BR, Cupisti A, D’Alessandro C, Bellasi A, Barbera V, Di Lullo L. Nutritional therapy in autosomal dominant polycystic kidney disease. *J Nephrol* (2018) doi:10.1007/s40620-018-0470-x
50. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in autosomal dominant polycystic kidney disease. *Kidney Int* (2013) 83:621–7. doi:10.1038/ki.2012.551
51. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. *N Engl J Med* (2017) 377:1930–42. doi:10.1056/NEJMoa1710030
52. The German ADPKD Tolvaptan Treatment Registry. *ClinicalTrials.gov* (2017). Available from: https://clinicaltrials.gov/ct2/show/NCT02495721 (accessed October 23, 2017)
53. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. *Nephrol Dial Transplant* (2016) 31:337–48. doi:10.1093/ndt/gfv456
54. Harris PC, Torres VE. Polycystic kidney disease. *Annu Rev Med* (2009) 60:321–37. doi:10.1146/annurev.med.60.101707.125712